Predictors for therapeutic effect of Lusutrombopag in chronic liver disease

Not Applicable

• Conditions: Chronic liver disease

• Registration Number: JPRN-UMIN000025776
• Lead Sponsor: Kitasato University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-01-20
• Study Completion: 2021-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients with a hematologic malignancy. 2.Active malignancy at time of study entry except HCC. 3.Patients who underwent liver transplantation 4.Patients with a severe liver dysfunction (Child-pugh C) 5.Patients with a medical history of thrombosis. 6.Patients with a medical history of thrombotic disease adult patients. 7.Women who are pregnant or breastfeeding 8.Severe GI bleeding. 9.Not appropriate for this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response rate (more than 50,000 /mm^3) at after adminstraion of lusutrombopag.

Secondary Outcome Measures

Name	Time	Method
1.Increase rate of Platelet count. 2.Correlation with increase rate and thrombopoietin. 3.Correlation with increase rate and megakaryocyte. 4.Correlation with increase rate and portal hypertention. 5.Adverse event occurrence rate.